Clinical trial
A Phase II, Open-Label, Multicenter Trial Comparing Disitamab Vedotin Plus Sintilimab and S-1 With Trastuzumab Plus Chemotherapy ± Sintilimab for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RCTS2)
NCT06730373 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Multicenter Trial Comparing Disitamab Vedotin Plus Sintilimab and S-1 With Trastuzumab Plus Chemotherapy ± Sintilimab for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RCTS2)
- Lead sponsor
- Qilu Hospital of Shandong University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 17, 2024
- Completion date
- December 31, 2027
- Enrollment
- 110 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
her2-positive gastric cancer, metastatic gastric cancer, unresectable gastric carcinoma